Sign In
Buy VYNE
$0.656
-0.0200 (-2.96%)
At Close: Jun 03, 2026
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
04:15pm, Wednesday, 01'st Nov 2023
Transformative capital raise to fund VYNE's BET inhibitor programs through the end of 2025 Transformative capital raise to fund VYNE's BET inhibitor programs through the end of 2025
VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202
07:20am, Monday, 30'th Oct 2023
BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovat
VYNE Therapeutics Announces Private Placement of $88 Million
07:05am, Monday, 30'th Oct 2023
Transaction provides $88 million to fund VYNE's clinical development programs for VYN201 and VYN202 through the end of 2025 Transaction provides $88 million to fund VYNE's clinical development program
BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovat
VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Wednesday, 06'th Sep 2023
BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing propriet
VYNE Gains on Preclinical Data for IPF Candidate
12:57pm, Thursday, 20'th Apr 2023
VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.
4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650%
10:32am, Wednesday, 19'th Apr 2023
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Analysts, Targets Up To 1,650% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
06:30am, Sunday, 16'th Apr 2023
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference
08:00am, Wednesday, 22'nd Mar 2023
BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing propriet
VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
08:00am, Friday, 18'th Nov 2022
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differ
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
06:48pm, Thursday, 10'th Nov 2022
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy
01:33pm, Wednesday, 17'th Aug 2022
VYNE Therapeutics Inc. (VYNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
08:00am, Wednesday, 18'th May 2022
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differe
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
07:34pm, Thursday, 12'th May 2022
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics to Present at LifeSci Partners' Immunology & Inflammation Symposium on May 10th
08:00am, Friday, 06'th May 2022
BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differe
